Just re-watched the 2023 presentation from Dr Maiti from MD Anderson clinic in the US re Advent NK MLA trial
a few points to note:
- MD Anderson is the premier cancer clinic in the US- Responsible for 9/10 latest FDA approvals for AML
- A successful trial with CHM NK allogenic cells will be practise changing
- targeting 1 st line therapy (in combination with existing standard of care)
- Rebecca alluded to early efficacy signals in the 1st cohort during her presentation at TechKnow.
- Rebecca also advised that trial is powering along
- MD Anderson gets 40 AML patients a month so enrolling patients won’t be difficult
- Dr Māiti provides strong rationale for why he pursued a collaboration with CHM
- Dr Maiti says a successful phase 1 , would likely result in a breakthrough designation from the FFA
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $12.99M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $949 | 312.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 67782438 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 91927011 | 27 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |